Here's why Gilead broke its dealmaking hiatus and splurged $12 billion on a cancer treatment

After several quiet years, Gilead made a splashy return to M&A Monday, buying cancer-immunotherapy firm Kite Pharma for $11.9 billion in cash, a 29% premium.